All Stories

  1. Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis

    Article • JCO Precision Oncology, July 2026, American Society of Clinical Oncology (ASCO)

    Sung Hee Lim

  2. Data from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  3. Supplementary Figure S1 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  4. Supplementary Figure S2 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  5. Supplementary Figure S3 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  6. Supplementary Figure S4 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  7. Supplementary Figure S5 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  8. Supplementary Figure S6 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  9. Supplementary Figure S7 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  10. Supplementary Table S1 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  11. Supplementary Table S2 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  12. Supplementary Table S3 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  13. Supplementary Table S4 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  14. Supplementary Table S5 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  15. Trial Protocol S1 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • June 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  16. EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer

    Article • Journal of Clinical Oncology, June 2026, American Society of Clinical Oncology (ASCO)

    Sung Hee Lim

  17. Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP–CDKN2A/B Deletion in Non-NSCLC Solid Tumors

    Article • Cancers, March 2026, MDPI AG

    Sung Hee Lim

  18. Data from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  19. Figure S1 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  20. Figure S2 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  21. Figure S3 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  22. Figure S4 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  23. Figure S5 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  24. Figure S6 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  25. Figure S7 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  26. Table S1 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  27. Table S2 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  28. Table S3 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  29. Table S4 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  30. Table S5 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1<sup>+</sup> Gastric Cancer

    Article • February 2026, American Association for Cancer Research (AACR)

    Sung Hee Lim

  31. Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer

    Article • Cancer Immunology Research, November 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  32. Prevalence and clinical implications of PIK3CA aberrations across cancer types: A real-world next-generation sequencing approach

    Article • Cancer Genetics, September 2025, Elsevier

    Sung Hee Lim

  33. Supplementary Figure S1 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  34. Supplementary Figure S2 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  35. Supplementary Figure S3 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  36. Supplementary Figure S4 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  37. Supplementary Figure S5 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  38. Supplementary Figure S6 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  39. Supplementary Figure S7 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  40. Supplementary Table S1 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  41. Supplementary Table S2 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  42. Supplementary Table S3 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  43. Supplementary Table S4 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  44. Supplementary Table S5 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  45. Trial Protocol S1 from Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • May 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  46. Determinants of Response to Sequential Pembrolizumab with Trastuzumab plus Platinum/5-FU in HER2-Positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial

    Article • Clinical Cancer Research, February 2025, American Association for Cancer Research (AACR)

    Sung Hee Lim

  47. Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy

    Article • Clinics, January 2025, Elsevier

    Sung Hee Lim

  48. Pulmonary Tumor Thrombotic Microangiopathy Associated With Gastric Cancer: Clinical Characteristics and Outcomes

    Article • Journal of Gastric Cancer, January 2025, XMLink

    Sung Hee Lim

  49. Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study

    Article • Journal of Urologic Oncology, March 2024, Korean Urological Oncology Society

    Sung Hee Lim

  50. Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data

    Article • Biomedicines, December 2023, MDPI AG

    Sung Hee Lim

  51. Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: A Real World Data

    Article • September 2023, MDPI AG

    Sung Hee Lim

  52. Clinical Experience of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients Aged 60 Years and Older in South Korea

    Article • Yonsei Medical Journal, January 2023, XMLink

    Sung Hee Lim

  53. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers

    Article • Journal of Korean Medical Science, January 2023, XMLink

    Sung Hee Lim

  54. Eight-Month Follow-up After the Third Dose of BNT162b2 Vaccine in Healthcare Workers: The Question of a Fourth Dose

    Article • Journal of Korean Medical Science, January 2023, XMLink

    Sung Hee Lim

  55. Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?

    Article • Journal of Korean Medical Science, January 2023, XMLink

    Sung Hee Lim

  56. The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer

    Article • Journal of Gastric Cancer, January 2023, XMLink

    Sung Hee Lim

  57. Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine

    Article • Vaccines, November 2021, MDPI AG

    Sung Hee Lim

  58. Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial

    Article • Yonsei Medical Journal, January 2021, XMLink

    Sung Hee Lim

  59. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease

    Article • Annals of Oncology, July 2017, Oxford University Press (OUP)

    Sung Hee Lim

  60. Characteristics and outcomes of ALK + non-small cell lung cancer patients in Korea

    Article • Asia-Pacific Journal of Clinical Oncology, April 2017, Wiley

    Keunchil Park, Sung Hee Lim

  61. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer withFGFR1amplification: A single-arm, phase 2 study

    Article • Cancer, June 2016, Wiley

    Sung Hee Lim

  62. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

    Article • European Journal of Cancer, January 2016, Elsevier

    Sung Hee Lim